The stock of Elevation Oncology Inc (ELEV) has gone down by -0.37% for the week, with a 21.65% rise in the past month and a 53.01% rise in the past quarter. The volatility ratio for the week is 3.46%, and the volatility levels for the past 30 days are 3.40% for ELEV. The simple moving average for the last 20 days is 2.67% for ELEV’s stock, with a simple moving average of -24.71% for the last 200 days.
Is It Worth Investing in Elevation Oncology Inc (NASDAQ: ELEV) Right Now?
The 36-month beta value for ELEV is at 1.50. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 7 as “hold,” and 0 as “sell.”
The public float for ELEV is 53.00M, and currently, shorts hold a 5.74% of that float. The average trading volume for ELEV on July 03, 2025 was 1.43M shares.
ELEV) stock’s latest price update
Elevation Oncology Inc (NASDAQ: ELEV) has experienced a rise in its stock price by 2.77% compared to its previous closing price of $0.37. However, the company has seen a fall of -0.37% in its stock price over the last five trading days. globenewswire.com reported 2025-06-15 that NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) — Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Elevation Oncology, Inc. (NASDAQ: ELEV) related to its sale to Concentra Biosciences, LLC. Under the terms of the proposed transaction, Elevation shareholders will receive $0.36 in cash per share, plus one non-tradeable contingent value right representing the right to receive: (i) 100% of the closing net cash in excess of $26.4 million; and (ii) 80% of any net proceeds received within five years following closing from any disposition of EO-1022 that occurs within one year following closing. Is it a fair deal?
Analysts’ Opinion of ELEV
Many brokerage firms have already submitted their reports for ELEV stocks, with Stephens repeating the rating for ELEV by listing it as a “Equal-Weight.” The predicted price for ELEV in the upcoming period, according to Stephens is $1 based on the research report published on March 24, 2025 of the current year 2025.
Piper Sandler, on the other hand, stated in their research note that they expect to see ELEV reach a price target of $0.70. The rating they have provided for ELEV stocks is “Neutral” according to the report published on March 21st, 2025.
Leerink Partners gave a rating of “Market Perform” to ELEV, setting the target price at $1 in the report published on March 21st of the current year.
ELEV Trading at 8.61% from the 50-Day Moving Average
After a stumble in the market that brought ELEV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.45% of loss for the given period.
Stock Fundamentals for ELEV
The total capital return value is set at -0.63. Equity return is now at value -78.32, with -50.20 for asset returns.
Currently, EBITDA for the company is -44.7 million with net debt to EBITDA at 1.26. The liquidity ratio also appears to be rather interesting for investors as it stands at 19.40.
Conclusion
In conclusion, Elevation Oncology Inc (ELEV) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
